Mutual Fund Series Trust Files Form 497K
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Thousands of US Flights Canceled and Delayed as Air Travel System Recovers
Thousands of US flights were canceled or delayed as the air travel system slowly recovered from a shutdown.
M impact | EQUITY | Nov 14, 2026, 06:37 PM UTC
Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound
The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC
Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds
Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC
Novo Nordisk CagriSema Reduced Waist Circumference by 17.2–17.5 cm
Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo.
M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC
Novo Nordisk CagriSema Shows Weight Loss in REDEFINE 9 Trial
At 68 weeks, average weight loss was 20.7% with 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo.
M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC
Novo Nordisk Says CagriSema Reduced Waist Circumference Up to 17.5 cm
Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo.
M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC